The combination of a c-myc inhibitor [38] or an inhibitor that suppresses c-myc transcription [39] and an NFκB inhibitor could be an effective approach to inhibit the transcription of cyclin B1, MMP13, and PTGS2, thereby preventing or limiting the progression of carcinogenesis in humans with early stage tongue cancers. Here, PTGS2 is linked to tongue cancer.